Table I.
Patients’ baseline characteristics according to reTURB status
| Parameter | All | reTURB | Without TURB |
|---|---|---|---|
| Gender: | |||
| F/M | 91 (18.5%)/400 (81.5%) | 42 (21.7%)/193 (71.3%) | 49 (19.1%)/207 (80.9%) |
| Primary diagnosis: | |||
| Ta/T1 | 114 (23.2%)/377 (76.8%) | 34 (14.5%)/201 (85.5%) | 80 (31.2%)/176 (68.3%) |
| HG/LG | 342 (69.6%)/149 (30.4%) | 211 (89.9%)/24 (10.1%) | 131 (51.2%)/125 (48.8%) |
| TaHG/T1HG/T1LG | 70 (14.3%)/272 (55.4%)/105 (21.4%) | 31 (13.2%)/180 (76.6%)/21 (8.9%) | 39 (15.2%)/92 (35.9%)/84 (32.8%) |
| T1 lamina propria: | |||
| Focal infiltration/massive infiltration | 282 (74.8%)/95 (25.2%) | 145 (72.1%)/56 (27.9%) | 137 (77.8%)/39 (22.2%) |
| Muscle in primary TURB specimen: | |||
| Yes/no/missing data | 355 (72.3%)/125 (25.5%)/11 (2.2%) | 179 (76.2%)/54 (23%)/2 (0.8%) | 176 (68.7%)/71 (27.8%)/9 (3.5%) |
| Concomitant CIS: | |||
| Yes/no | 89 (18.1%)/402 (81.9%) | 35 (14.9%)/200 (85.1%) | 54 (21%)/202 (79%) |
| Number of tumours: | |||
| Solitary/multiple | 222 (45.2%)/269 (54.8%) | 113 (48%)/122 (52%) | 109 (42.6%)/147 (57.4%) |
| EORTC risk group: | |||
| Intermediate/high | 54 (11%)/437 (89%) | 2 (0.8%)/233 (99.2%) | 52 (20.3%)/204 (79.7%) |
| Tumour size: | |||
| < 3 cm/> 3 cm | 300 (61.1%)/191 (38.9%) | 146 (62.1%)/89 (37.8%) | 154 (60.2%)/102 (39.8%) |
| Newly diagnosed/recurrent | 246 (50.1%)/245 (49.9%) | 133 (56.6%)/102 (43.4%) | 113 (44.1%)/143 (55.9%) |
| Observation time, median (IQR) | 34 (33–62) | 71 (35–118) |
F – female, M – male, TURB – transurethral resection of bladder tumour, CIS – carcinoma in situ, IQR – interquartile range; missing data only when stated.